Skip to main content
Explore URMC

Wilmot Cancer Institute Logo

menu
The Future of Esophageal Cancer: Clinical Trials at Wilmot Attempt to Improve Treatments

The Future of Esophageal Cancer: Clinical Trials at Wilmot Attempt to Improve Treatments

Researchers at Wilmot Cancer Institute are working to improve treatment for esophageal cancer, a disease that affects 17,000 Americans each year. Often diagnosed after the cancer has spread, the disease has a low five-year survival rate.

From AML to Ph.D.: How Wilmot helped one patient diagnosed with leukemia

From AML to Ph.D.: How Wilmot helped one patient diagnosed with leukemia

Ege Ozen was working toward his Ph.D. in Political Science when he was diagnosed with acute myeloid leukemia (AML). His oncology team at Wilmot and his wife have helped him through, and he achieved his goal of earning his Ph.D. in 2016. He's now a tenure-track professor at the College of Staten Island, CUNY. 

Four things to know about prostate cancer

Four things to know about prostate cancer

Prostate cancer is the most common cancer among men in the U.S. Each year, approximately 161,000 men in the U.S. are diagnosed with this type of cancer, including approximately 630 in Monroe County alone. Our prostate cancer specialists shared a few important facts everyone should know when it comes to prostate cancer.

Lymphoma: Targeting treatment for special populations

Lymphoma: Targeting treatment for special populations

Patrick Reagan, M.D., is working with Wilmot's Geriatric Oncology team, to develop a targeted approach for treating older adults with diffuse large B-cell lymphoma.

Lymphoma: Looking for Clues in the Immune System

Lymphoma: Looking for Clues in the Immune System

Wilmot researchers are studying the non-cancer cells in a tumor — known as the tumor microenvironment — to learn more about the important role they play in the course of lymphoma.